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Pancreatic cancer is a devastating disease with an unacceptably high mortality to
incidence ratio. Traditional therapeutic approaches such as surgery in combination with
chemo- or radiotherapy have had limited efficacy in improving the outcome of this
disease. Up until just under a decade ago, the prominent desmoplastic reaction which
is a characteristic of the majority of pancreatic ductal adenocarcinomas (PDAC) had
been largely ignored. However, since the identification of the pancreatic stellate cell
(PSC) as the key cell responsible for the production of the collagenous stroma in PDAC,
increasing attention has been paid to the role of the stromal reaction in pancreatic
cancer pathobiology. There is now compelling evidence that PSCs interact not only with
cancer cells themselves, but with several other cell types in the stroma (endothelial cells,
immune cells, and possibly neuronal cells) to promote cancer progression. This review
summarizes current knowledge in the field about the influence of PSCs and the stromal
microenvironment on cancer behavior and discusses novel therapeutic approaches which
reflect an increasing awareness amongst clinicians and researchers that targeting cancer
cells alone is no longer sufficient to improve patient outcome and that combinatorial
treatments targeting the stroma as well as the cancer cells will be required to change
the clinical course of this disease.
Keywords: pancreatic cancer, pancreatic stellate cells, desmoplastic/stromal reaction, stromal-tumor interactions,
stromal therapeutic targets
INTRODUCTION
Pancreatic cancer (pancreatic ductal adenocarcinoma; PDAC) is a
lethal disease. It is the fourth leading cause of cancer related death
in developed countries (Jemal et al., 2011; Siegel et al., 2013).
Five year survival is at best 6% and survival beyond 12 months is
unusual. Only 20% of patients are deemed suitable for attempted
curative resection. Chemotherapy confers marginal benefit while
the benefit of radiotherapy is debated. There are several reasons
for this grim outlook. As the pancreas is a retroperitoneal organ,
cancers in its body and tail present late, often with considerable
local and distant spread. Early symptoms are often non-specific.
There are no biomarkers for the disease.
Risk factors for pancreatic cancer include age, smoking, race,
diabetes, and chronic pancreatitis. The strongest known risk fac-
tor for pancreatic cancer is chronic pancreatitis. Patients with a
history of more than 5 years chronic pancreatitis have a greater
than 14-fold risk of developing pancreatic cancer compared to the
general population (Chu et al., 2007; Pandol et al., 2012). A signif-
icant proportion (40%) of patients with hereditary pancreatitis is
at increased risk of developing pancreatic cancer (Whitcomb and
Greer, 2009). For patients with tropical pancreatitis, a 100-fold
increased risk and an earlier onset of pancreatic cancer has been
reported (Chari et al., 1994; Whitcomb, 2004). The mechanisms
underlying this increased propensity for patients with chronic
pancreatitis to develop pancreatic cancer are not fully elucidated
although recent studies suggest that several signaling pathways
known to be active in inflammatory disease may be involved in
driving this process (Thomasova et al., 2012).
Histologically, PDAC is characterized by an extensive and
dense desmoplastic/fibrotic stroma in which cancer cells are
embedded (Figure 1). It has now been unequivocally shown that
the principal effector cells responsible for the production of this
stroma are pancreatic stellate cells (PSCs) (Apte et al., 2004).
Considerable evidence has also accumulated in recent years to
indicate that this abundant stroma can no longer be considered
a mere bystander in pancreatic cancer pathobiology, but should
be recognized as a critical player in cancer progression.
This review will concentrate on the interactions between PSCs
and pancreatic cancer cells and will also touch upon recent
reports about the interactions between PSCs and other stromal
cells (endothelial, immune, and nerve cells), all of which have
the potential to influence local growth and distant spread of
pancreatic tumors.
PANCREATIC STELLATE CELLS (PSCs)
PSCs were first described by Watari et al. (1982). These resident
cells of the pancreas are predominantly periacinar in location
and comprise 4–7% of total pancreatic parenchymal cells. In the
healthy pancreas, PSCs are in a quiescent state and exhibit abun-
dant vitamin A containing lipid droplets in their cytoplasm (Apte
et al., 1998). Similar cells exist in the liver—hepatic stellate cells
(HSCs). HSCs were first described by Kupffer in 1876 but were
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FIGURE 1 | Histology of pancreatic cancer: Hematoxylin and eosin
stained section of a human pancreatic cancer section showing tumor
elements (thin arrows) embedded in an abundant collagenous stroma
(thick arrows) (previously unpublished figure).
brought into modern prominence by the work of Ito (1951) and
Wake et al. (1987). Since that time, HSCs have been acknowledged
as the principal site of storage of vitamin A in the body as well as
being (when activated) the principal effector cells of liver fibro-
sis. It is now well-established that HSCs have a range of functions
encompassing extracellular matrix (ECM) homeostasis, fibrosis,
retinoid metabolism, liver development and regeneration, and
immunomodulation (Lee and Friedman, 2011).
PSCs were first isolated by Apte et al. (1998) and this achieve-
ment opened up the field of pancreatic fibrogenesis as the cells
could now be studied in vitro and in vivo. Since 1998, PSCs have
been extensively characterized and their roles in fibrogenesis and
tumor stromal interactions have been delineated in some detail
(Apte et al., 2012).
PSCs express desmin, glial fibrillary acid protein (GFAP),
vimentin, and nestin (intermediate filament proteins) as well as
the neuroectodermal markers such as nerve growth factor (NGF)
and neural cell adhesion molecule; the expression of these selec-
tive markers differentiates PSCs from fibroblasts (Figure 2). At
the ultrastructural level they feature a prominent rough endoplas-
mic reticulum, collagen fibrils, and lipid droplets surrounding a
central nucleus. With their ability to produce ECM proteins as
well as the enzymes that degrade ECM proteins [matrix metallo-
proteinases (MMPS)], and inhibitors of MMPs [tissue inhibitors
of metalloproteinases (TIMPS)], PSCs are thought to play a pri-
mary role in maintenance of normal pancreatic architecture.
However, when activated, during pancreatic injury, the cells lose
their lipid droplets, express α-smooth muscle actin (α-SMA),
proliferate, migrate, and produce excessive amounts of ECM pro-
teins, resulting in a loss of the balance between ECM production
and degradation and leading eventually to fibrosis. During an
acute episode of pancreatic injury, PSCs are activated early, and
secrete excess ECM proteins that lay down a lattice for regener-
ating epithelial cells. As the injury resolves, activated PSCs are
lost most likely through apoptosis (Tahara et al., 2008; Vonlaufen
et al., 2011). MMPs secreted by the remaining PSCs degrade
the excess fibrosis resulting in restitution of normal pancreatic
histology. However, with repeated or sustained injury, PSCs can
attain a perpetually activated state, since the cells can secrete their
own cytokines and growth factors, which in turn can activate
PSCs via selected receptors on the cell surface (Mews et al., 2002;
Masamune et al., 2009). Thus, even in the absence of the original
triggers, PSCs can remain in their activated state eventually being
responsible for the development of pathological, often irreversible
fibrosis.
While most of the initial research attention was directed
toward elucidating the mechanisms responsible for PSC-
mediated pancreatic fibrosis, it is becoming increasingly clear that
PSCs may have several additional functions in health and disease.
These include:
i. Role in pancreatic exocrine secretion: The secretagogue chole-
cystokinin (CCK) has been shown to directly stimulate
exocrine secretion from rodent pancreatic acinar cells by
binding to CCK receptors on the cell surface. However, there
has been some controversy in the published literature regard-
ing the direct effects of CCK on human pancreatic acinar
cells, with Ji et al. reporting in 2001 and 2002 (Ji et al.,
2001, 2002) that human acinar cells did not exhibit func-
tional CCK receptors, a finding that was later countered
by Murphy et al. (2008) who reported that isolated human
pancreatic acini responded to physiological CCK concentra-
tions by exhibiting the expected oscillatory rise in cytosolic
calcium and by secreting amylase. In view of the close asso-
ciation of PSCs with the basolateral aspects of acinar cells, it
has been postulated that in the human pancreas, PSCs may
provide an alternative/additional pathway for CCK-mediated
enzyme secretion by acting as intermediary cells in the CCK-
stimulated secretory pathway. This concept is supported by
the observations that (a) PSCs express both types of (CCK)
receptors; (b) upon exposure to CCK, PSCs synthesize and
secrete acetylcholine which can then act on muscarinic recep-
tors on acinar cells leading to digestive enzyme release; and (c)
PSC-mediated amylase secretion by acinar cells can be inhib-
ited by the muscarinic receptor antagonist, atropine (Phillips
et al., 2010).
ii. Role in innate immunity (Masamune et al., 2008a; Shimizu
et al., 2012): PSCs express Toll-like receptors (TLR 2, 3, 4, 5,
and 9) which recognize foreign pathogen-associated molec-
ular patterns (PAMPs) and have been shown to be able to
phagocytose necrotic and apoptotic cells. These functions
suggest that the cells may have an “innate” immune func-
tion which protects local parenchyma, thereby limiting tissue
damage during early pancreatic injury. However, the role of
PSCs in acquired immunity is not as clear. Unlike their hep-
atic counterparts, PSCs do not express any antigen-presenting
cell markers such as MHC class II or HLA-DR molecules.
The reason for this difference between HSCs and PSCs is
not known, but may reflect the fact that HSCs are rou-
tinely exposed to numerous antigens via the portal circulation
resulting in the cells acquiring functions of antigen presenting
cells, while PSCs are relatively protected within the pancreas.
iii. Role as progenitor cells (Mato et al., 2009; Kordes et al., 2013):
Mato et al. (2009) used mitoxantrone (a compound that acts
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FIGURE 2 | Human pancreatic stellate cells (PSCs) in culture. Immunocytochemical analysis of primary cultures of human PSCs exhibiting desmin and glial
fibrillary acidic protein (GFAP) staining. Insets: Negative control (previously unpublished figure).
through multidrug transport systems) to isolate and expand
a population of mitoxantrone-resistant pancreatic cells from
lactating rats. They reported that these selected cells exhibited
a morphology identical to PSCs, with vitamin-A contain-
ing lipid droplets in the cytoplasm. The cells also expressed
ABCG2 transporter (ATP-binding cassette G2 transporter—
a stem cell marker) and when incubated with an appro-
priate differentiating medium, were able to secrete insulin.
More intriguingly, a recent study by Kordes et al. (2013) has
reported that clonally expanded rat PSCs, when injected into
hepatectomized recipient rats, were able to migrate to the
liver and to reconstitute large parts of the liver by differen-
tiating into hepatocytes and cholangiocytes, whereas muscle
fibroblast did not show any such transformations.
iv. Role in cancer progression (Apte et al., 2013): There is now
incontrovertible evidence from both in vivo and in vitro stud-
ies for a central role for PSCs in promoting local growth of
pancreatic tumors as well as facilitating regional and distant
spread of pancreatic cancer cells.
INTERACTIONS BETWEEN PSC AND PANCREATIC CANCER
CELLS, ENDOTHELIAL CELLS, IMMUNE CELLS, AND NEURAL
CELLS
EVIDENCE FROM IN VIVO STUDIES
The role of PSCs in pancreatic cancer biology was initially stud-
ied in xenograft models and more recently has been examined
using transgenic animal models of the disease. The earliest study
in this area was published by Bachem et al. (2005), who used a
subcutaneous xenograft model in immunocompromised mice to
demonstrate increased growth of pancreatic cancer cells when co-
injected with PSCs into the flanks of mice. The tumors produced
in mice injected with both cell types were significantly larger than
those inmice injected with cancer cells alone, exhibiting increased
fibrosis as well as enhanced cancer cell proliferation. These obser-
vations suggested that, in addition to producing the collagenous
stroma, PSCs also directly stimulated cancer cell growth.
Although the above findings were of interest, it is well-known
that subcutaneous xenograft models of pancreatic cancer have an
important limitation—the natural tumor microenvironment is
absent in these models. Therefore, orthotopic tumors produced
by implantation/injection of cancer cells directly into the pan-
creas are a preferred option. Such cells would be exposed to the
samemicroenvironment as may be expected in human pancreatic
cancer and would also have the capacity to metastasize, further
simulating the human condition.
In recent years, several studies have reported orthotopic mod-
els of pancreatic cancer involving direct implantation/injection
into the mouse pancreas of human pancreatic cancer cells
(MiaPaCa-2, BxPC-1, AsPC-1) with or without human PSCs
(hPSCs) (Hwang et al., 2008; Vonlaufen et al., 2008a; Xu et al.,
2010). The presence of hPSCs enhanced local tumor growth as
well as regional and distant metastasis. Tumors composed of both
cancer cells and hPSCs exhibited (i) bands of fibrosis (resem-
bling desmoplasia) containing α-SMA positive (activated) PSCs
(Figure 3); and (ii) increased proliferation and decreased apopto-
sis of cancer cells, suggesting that the presence of PSCs increased
the survival of cancer cells. These observations concur with those
seen with hPSCs and tumor cells in vitro (vide infra) and support
a role for PSCs in pancreatic cancer progression.
Orthotopic tumors produced by cancer cells + PSCs also
exhibited enhanced angiogenesis (as indicated by the upregula-
tion of the endothelial cell marker CD31) compared to tumors
produced by the injection of cancer cells only, suggesting that
PSCs stimulate angiogenesis in pancreatic cancer (Xu et al., 2010).
It must be noted here however, that angiogenesis in human pan-
creatic cancers may be more complex than that observed in
orthotopic models. Indeed, the central areas of advanced pan-
creatic tumors in humans are known to be very poorly perfused
and hypoxic, with only a few blood vessels evident on histologi-
cal examination; it is only the invading front of the cancers that
manifests neoangiogenesis (Erkan et al., 2009). These findings
are supported by in vitro work indicating that while the induc-
tive effect of PSCs on angiogenesis is well-demonstrated under
normoxic conditions, the same cannot be demonstrated under
hypoxic conditions (Erkan et al., 2009). Thus, the overall influ-
ence of PSCs on angiogenesis in pancreatic cancer (taking into
account the differences in oxygenation within the tumor) remains
to be fully clarified.
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FIGURE 3 | Orthotopic pancreatic tumor produced by injecting a mixture
of human pancreatic cancer cells (MiaPaCa-2) and human pancreatic
stellate cells into the pancreas of nude mice. (A) H and E staining of tumor
section showing prominent areas of fibrosis (desmoplasia) within the tumor.
Reprinted with permission Vonlaufen et al. (2008a). (B) Fibrosis was
quantitated by morphometry of Masson’s stained sections (not shown). The
graph depicts the significant increase in fibrosis in tumors produced by
injection of a mixture of PSCs and cancer cells (MiaPaCa-2), compared to
cancer cells alone. *p < 0.02; n = 10 mice/group (previously unpublished
data).
One of the well-documented features of human pancreatic
cancer is its resistance to chemotherapeutic agents and to radio-
therapy. It is possible that this resistance may be mediated, at
least in part, by the dense stroma produced by PSCs (Hanahan
and Weinberg, 2011). In support of this notion, it has been
shown that sequestration of chemotherapeutic agents such as
gemcitabine can occur in the tumor stroma, effectively reduc-
ing the amount of the drug that can reach cancer cells (Olive
et al., 2009). Furthermore, Mantoni et al. (2011) have reported
that PSCs protect cancer cells from radiation via a β1-integrin
dependent pathway.
As indicated above, in orthotopic models, PSCs have been
shown to promote tumor metastasis. Traditionally, only cancer
cells have been thought to possess metastatic capabilities, which
allow the cells to intravasate into blood vessels or lymphatics,
travel through the circulation, and extravasate at distant sites.
This concept has been challenged by the findings of Xu et al.
(2010) who, using a gender mismatch approach have demon-
strated that PSCs from the primary tumor can also be detected
at distant metastatic sites. The authors injected a mixture of
male human PSCs and female cancer cells (AsPC-1 cell line
from a female patient), into the pancreas of female mice. Using
fluorescent in situ hybridization, y chromosome positive cells
were detected not only in the primary tumors (as expected) but
also within metastatic nodules in the mediastinum, liver, and
diaphragm. These observations indicate that PSCs can travel to
distant metastatic sites (possibly with cancer cells), where they
may be reasonably postulated to play a role in the seeding,
survival, and proliferation of cancer cells. A subsequent study
reported similar findings in a model of lung cancer (Duda et al.,
2010) suggesting that metastasis can no longer be considered the
sole preserve of cancer cells.
In contrast to subcutaneous and orthotopic models where
tumors are produced in immunocompromised mice by
xenografts of human pancreatic cancer cells and PSCs, some
genetically engineered mouse (GEM) models exhibit the devel-
opment of spontaneous pancreatic cancer with a prominent
endogenously produced stromal reaction (Guerra and Barbacid,
2013). These models include KPC mice (KrasLSL−G12D/+;
Trp53LSL−R172H/+; Pdxcre/+), KPGC mice (KrasLSL−G12D/+;
Trp53LSL−R172H/+; R26LSL−GFP/+; Pdxcre/+), and TGFβ type
II receptor organ specific knockout in the mouse pancreas
(KrasLSL−G12D/+; TGFβr2floxflox; Ptf1acre/+). The lesions in these
models progress from preinvasive ductal changes (PanIN lesions)
to overt carcinoma and metastases, with an associated progres-
sive increase in the surrounding stromal reaction. Importantly,
activated PSCs have been observed in the earliest PanIN lesions
(Ijichi et al., 2011; Apte et al., 2013). These GEM models provide
an additional in vivo tool to assess the interactions between
cancer cells and an endogenous stromal reaction and also to trial
new therapeutic strategies in pancreatic cancer.
Evasion of the immune system is a well-recognized feature
of pancreatic cancer (Bayne et al., 2012). Pancreatic cancer tis-
sue is infiltrated with immune cells, such as T cells, B cells, NK
cells, neutrophils, and macrophages as well as myeloid-derived
suppressor cells (as the name suggests, MDSCs have a largely
immunosuppressive function) (Apte et al., 2013; Ene-Obong
et al., 2013; Hamada et al., 2013; Ino et al., 2013). Higher levels
of CD8+ T cell infiltration have been shown to correlate with a
better survival (Ene-Obong et al., 2013; Ino et al., 2013), while
macrophage and neutrophil infiltration as well as high levels of
MDSCs have been reported to be associated with poor survival
(Gabitass et al., 2011; Ino et al., 2013). It has been demonstrated
that cancer cells can evade the host immune system by producing
granulocyte-macrophage colony-stimulating factor to suppress
anti-tumor T cell immunity (Bayne et al., 2012).
Recent studies suggest that PSCs may also aid immune eva-
sion. PSCs in the stroma of PanIN lesions and around cancer
cells produce galectin-1, a β-galactoside-binding protein (Chen
et al., 2012), that binds to N-acetyllactosamine on membrane
Frontiers in Physiology | Gastrointestinal Sciences February 2014 | Volume 5 | Article 52 | 4
Wilson et al. Role of stroma in pancreatic cancer
glycoproteins and induces apoptosis in T cells thus suppress-
ing the immune response (Tang et al., 2012). Ene-Obong et al.
(2013) have reported that activated PSCs reduce the migra-
tion of CD8 positive T cells toward cancer cells in both human
PDAC and the KPCmouse model of pancreatic cancer. Fibroblast
activation protein-α (FAP-α), known to be expressed by stro-
mal cells, is another protein that has been reported to disrupt
anti-tumor immunity. Depletion of the cells expressing FAP-α
enabled immune response-associated tumor regression, support-
ing the notion that FAP-α might act as an immune suppressor in
pancreatic cancer (Kraman et al., 2010). Most recently, another
type of immune cell, the mast cell, has been reported to play
a role in pancreatic cancer progression. Using an orthotopic
model of pancreatic cancer, Chang et al. (2013) have reported
that cancer growth is significantly hampered in mast cell defi-
cient Kit mice, while the reconstitution of mast cells in these
mice from the bone marrow of wild type mice significantly
enhanced tumor growth. Interestingly, as detailed later in this
review, PSCs have been shown to activate mast cells in vitro (Ma
et al., 2013), suggesting cross-talk between these two cell types in
the stroma.
Taken together, the above studies suggest that PSCs may nega-
tively modulate immune responses.
EVIDENCE FROM VITRO STUDIES
Findings derived from mouse models and observations on
resected human tissue are supported by a number of in vitro
studies which have confirmed a close bi-directional interaction
between pancreatic cancer cells and PSCs.
When PSCs are exposed to cancer cells (either by co-culture
or by using conditioned media), they are activated and man-
ifest increased proliferation, migration, and ECM production
(Apte and Wilson, 2012). In turn, PSCs stimulate cancer cell
proliferation and inhibit cancer cell apoptosis thereby facilitat-
ing cancer cell survival (Vonlaufen et al., 2008b). PSCs have
also been shown to promote cancer cell migration, during which
cancer cells exhibit features of epithelial-mesenchymal transition
(EMT) namely, decreased levels of epithelial markers such as
E-cadherin concurrent with increased expression of mesenchy-
mal markers (vimentin and Snail) (Fujiwara et al., 2013). It is
possible that EMT is responsible (at least in part) for the PSC-
induced increasedmigration of cancer cells. Most recently, a study
by Bachem et al. (Lu et al., 2014) has demonstrated that PSC-
induced cancer cell migration is dependent on collagen I secreted
by PSCs; interaction of cancer cells with collagen I enhances the
α2/β1 integrin-focal adhesion kinase (FAK) signaling pathway
that regulates migration of cancer cells.
While the above effects of PSCs on cancer cells are of signif-
icant interest, researchers have also been mindful of the known
heterogeneity of pancreatic cancer with respect to rate of pro-
gression. This has led to studies examining whether all PSCs
uniformly exert the same effects on cancer cells. Interestingly, a
subpopulation of PSCs that express CD10 (a cell membrane asso-
ciated matrix metalloproteinase), has been reported to induce
significantly greater effects on cancer cell proliferation and inva-
sion than CD10− PSCs (Ikenaga et al., 2010). These findings
indicate that functional heterogeneity between PSC populations
may dictate the ultimate effects of these cells on cancer cell
behavior.
One of the major factors responsible for the poor prognosis
of pancreatic cancer is its propensity for recurrence, with recur-
rent tumors postulated to arise from a niche of drug resistant
cancer stem cells. Recent evidence suggests that PSCs may play
a role in facilitating such a stem cell niche in pancreatic cancer.
Hamada et al. (2012) have reported that pancreatic cancer cells
in co-culture with PSCs show increased expression of stem cell
related genes such as nestin, ABCGZ, and LIN28, supporting the
possibility that a PSC-facilitated cancer stem cell niche may be
one of the factors responsible for recurrence of pancreatic cancer.
As the interactions between cancer cells and PSCs have become
increasingly recognized, factors mediating these interactions have
also attracted much interest. The increased proliferation of
PSCs induced by cancer cells is likely mediated by platelet-
derived growth factor (PDGF, a known mitogen for many cell
types), which stimulates mitogen-activated protein kinase signal-
ing (MAPK) in PSCs (Vonlaufen et al., 2008a). Recent studies
have also implied that cancer cell-stimulated PSC proliferation is
mediated by cyclooxygenase 2 (the inducible form of cyclooxy-
genases, which are enzymes involved in the conversion of arachi-
donic acid to prostaglandin Yoshida et al., 2005) and by trefoil
factor 1 (a stable secretory protein that is upregulated in pancre-
atic cancer but is not expressed in normal pancreas) (Arumugam
et al., 2011). The increase in ECM synthesis by PSCs upon expo-
sure to cancer cells is thought to be mediated by transforming
growth factor beta 1 (TGFβ1) and fibroblast growth factor 2
(FGF2) (Bachem et al., 2005).
Factors mediating the effects of PSCs on cancer cells remain
to be fully elucidated. Since cancer cells express receptors for
PDGF and PSCs have the capacity to secrete PDGF, it has been
postulated that this growth factor mediates the PSC-induced pro-
liferation of cancer cells (Vonlaufen et al., 2008a). PSCs also
secrete a cell adhesion protein named periostin, which has been
found to increase the growth of cancer cells and their resistance
to serum starvation and hypoxia (Erkan et al., 2007). Other can-
didate mediators that require further study include growth factors
such as EGF, insulin-like growth factor (IGF), hepatocyte growth
factor (HGF), and TGFβ as well as a variety of proinflamma-
tory cytokines. Notably, ERK1/2 and Akt have been identified as
the intracellular signaling pathways that regulate the response of
cancer cells (increased migration, invasion, and colony forma-
tion) to PSC secretions (Hwang et al., 2008; Vonlaufen et al.,
2008a).
The observed effects of PSCs on angiogenesis and metastatic
spread in vivo (described earlier) are strongly supported by
in vitro studies. PSCs have been shown to stimulate tube
formation (a measure of angiogenesis) of human microvascu-
lar endothelial cells, an effect mediated by vascular endothe-
lial growth factor (VEGF) secreted by PSCs (Xu et al., 2010).
Under normoxic conditions, PSCs also induce endothelial cell
proliferation, an effect again mediated by VEGF (Erkan et al.,
2009). However, this proliferative effect of PSCs on endothe-
lial cells was inhibited under hypoxic conditions (simulating the
hypoxia in the center of a dense desmoplastic stroma), partic-
ularly in the presence of cancer cells (Erkan et al., 2009). On
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the other hand, hypoxia itself was shown to significantly increase
PSC activation and ECM synthesis (Masamune et al., 2008b).
Thus, the interplay between vessel density/oxygenation at dif-
ferent sites within the tumor (central vs. peripheral) and PSC
activation, as well as the influence of PSCs on endothelial cell
function under varying oxygen concentrations requires further
study.
The ability of PSCs to travel from the primary tumor to
metastatic sites (noted earlier) implies that PSCs can migrate
through an endothelial layer. Using a Boyden chamber method
with a porous membrane coated by a monolayer of endothe-
lial cells, Xu et al. (2010) have shown that PSCs can invade
and migrate through the endothelial cell layer, an effect that is
enhanced in the presence of cancer cell secretions. This cancer
cell-induced transendothelial migration of PSCs is mediated by
PDGF in cancer cell secretions.
As noted earlier, pancreatic cancer cells have the ability to
escape immune surveillance despite the presence of significant
leukocyte infiltration in the stroma. There is in vivo evidence to
suggest that PSCs may play a role in this immune evasion by
sequestering CD8+ T cells and reducing their infiltration around
tumor cells, thus preventing the T cells from exerting their anti-
tumor effects. In vitro support for this concept comes from studies
showing that PSCs exert a chemotactic effect on CD8+ T cells,
and that this effect is mediated by the PSC-derived chemokine
CXCL12 (Ene-Obong et al., 2013). Interactions between PSCs
and mast cells have also been recently characterized (Ma et al.,
2013). PSCs have been shown to activate mast cells in vitro pro-
moting tryptase and IL13 release from the latter; these mast
cell-derived factors have been shown to stimulate cancer cell
proliferation. Mast cells also induce PSC proliferation, an effect
mediated by IL13. Most recently, IL6 secreted by PSCs has been
implicated in PSC-induced migration of the immunosuppressive
cells MDSCs (Mace et al., 2013); as noted previously, high levels
of MDSCs in pancreatic cancer tissue have been associated with
reduced overall survival (Gabitass et al., 2011).
Compared to the interactions of PSCs with cancer cells,
endothelial cells, and immune cells described above, little is
known about the interaction of PSCs with neural elements in
the desmoplastic reaction. However, extensive neural remodel-
ing is known to occur in pancreatic cancer with the cancer
stroma revealing neural hypertrophy and increased neural den-
sity (Ceyhan et al., 2010). It noteworthy that PSCs themselves
express the neural markers GFAP and nestin, and also produce
the neurotrophic factors NGF, brain-derived neurotrophic factor,
and neurotrophin 45 (Haas et al., 2009; Demir et al., 2012). Thus,
it would be reasonable to postulate that PSCs may act as neu-
ral elements in the tumor stroma, affecting the growth of nerves
(via secretion of ECM components collagen and fibronectin and
the neurotrophic factors noted above) and survival of cancer cells
that express receptors for neurotrophic factors. This hypothesis
is supported by a report by Ceyhan et al. (2009) demonstrating
a positive correlation between the extent of desmoplasia and the
degree of neural invasion in human PDAC.
Figure 4 summarizes the interactions between PSCs and pan-
creatic cancer cells as well as those between PSCs and other
stromal cells that may promote cancer growth and spread.
DO PANCREATIC STELLATE CELLS PLAY A ROLE IN THE
EARLIEST STAGES OF PANCREATIC CANCER?
While the role of PSCs in advanced pancreatic cancer is now well-
accepted, evidence is also accumulating to suggest that PSCs may
be activated at the earliest stages of pancreatic carcinogenesis,
i.e., around PanIN lesions. Pandol et al. (2012) have described
a distinct stromal reaction comprising extensive collagen depo-
sition and α-SMA positive activated PSCs around PanIN lesions
(Figure 5) which eventually lead to overt pancreatic cancer in a
mouse model overexpressing KrasG12D. Similarly periostin (solely
expressed by PSCs) has been observed in intraductal papillary
mucinous neoplasms of the human pancreas (Fukushima et al.,
2008), further supporting the idea that PSCs are activated early
in the neoplastic process. Recent in vitro studies have confirmed
an interaction between PanIN cells and PSCs. Exposure of PSCs
to PanIN cells isolated from KrasG12D mice significantly increased
PSC proliferation, activation (α-SMA), fibronectin synthesis, and
MMP expression (Pandol et al., 2012), indicating that preneoplas-
tic cells have the capacity to activate PSCs in the early stages of
carcinogenesis.
Based on findings reported by Funahashi et al. (2007), recip-
rocal effects of PSCs on PanIN cells which could facilitate pro-
gression to overt PDAC may also be postulated. The authors have
shown that nimesulide, a selective inhibitor of COX-2 (which
as noted earlier, is expressed by PSCs and implicated in PSC-
cancer interactions), retards the progression of pancreatic cancer
precursor lesions in a GEMmodel.
THERAPEUTIC TARGETING OF STROMA IN PANCREATIC
CANCER
Clinical outcome in pancreatic cancer has not improved sig-
nificantly over many decades. The usual regimens of surgery,
radiotherapy, and chemotherapy benefit only a small minority of
patients, and even in these patients, the chances of recurrence and
emergence of chemoresistant cancers are high. The majority of
patients are either not suitable for surgery at diagnosis or develop
resistance to single chemotherapeutic agents. In a bid to address
drug resistance, combination therapies have been trialed where
the standard chemotherapeutic agent gemcitabine is combined
with other agents such as Folfirinox (comprising 5-fluorouracil,
leucovorin, irinotecan, and oxaliplatin) or with targeted drugs
such as growth factor inhibitors or with soluble taxanes such as
Abraxane. The most recent studies combining gemcitabine with
Abraxane (nab-Paclitaxel) (Von Hoff et al., 2013) or Folfirinox
(Conroy et al., 2011) have reported an increase in overall survival,
but the benefit is marginal (a few months increased survival).
Thus, it is clear that a new approach is required to improve the
prognosis of this disease.
For reasons already discussed, strategies are now being devel-
oped to target not only cancer cells but also the desmoplastic
reaction, and initial studies have been focused on ways to inhibit
PSC activation.
One of the signaling factors known to mediate PSC activation
is the Hedgehog pathway (which is essential for embryonic devel-
opment, but usually not detectable in adult healthy pancreas)
(Bailey et al., 2008). This pathway has been also been implicated
in stem cell regulation and neoplasia (Thayer et al., 2003). Binding
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FIGURE 4 | Schematic diagram depicting the interactions between
activated pancreatic stellate cells and pancreatic cancer cells, as well as
pancreatic stellate cells and other stromal cells (endothelial cells,
immune cells, and neuronal cells), all of which may promote pancreatic
cancer progression. The dashed arrow between PSCs and neuronal cells
indicates that although an interaction between these two cell types may be
reasonably postulated, direct experimental evidence in support of this
concept has not yet been reported. Abbreviations: PSCs, pancreatic stellate
cells; MC, mast cells; MDSC, myeloid derived suppressor cells; ECM,
extracellular matrix.
FIGURE 5 | Presence of α-smooth muscle actin positive activated
pancreatic stellate cells in stroma surrounding early PanIN lesions in
(A) humans and (B) transgenic mice. Reprinted with permission Apte
et al. (2013).
of the Hedgehog ligand (Sonic, Indian, and Desert Hedgehog) to
its receptor Patched releases the co-receptor Smoothened from
repression and results in translocation of the transcription factor
Gli-1 from the cytoplasm to the nucleus where it regulates genes
involved in cell differentiation, proliferation, apoptosis, adhesion,
and migration. Abnormal activation of Hedgehog pathway has
been reported in several cancers including basal cell carcinoma,
lung, prostate, and pancreatic cancer. Inhibition of Smoothened
by cyclopamine or its derivative IPI-926 in transgenic mod-
els of pancreatic cancer has been recently studied (Feldmann
et al., 2007; Olive et al., 2009). Cyclopamine marginally increased
median survival by 6 days, while treatment of mice with IPI-926
in combination with gemcitabine, resulted in increased delivery
of the chemotherapeutic agent to cancer cells, but had only a
transient effect on improved blood vessel density and extension of
median survival. Subsequently, Hwang et al. (2012) used another
Smoothened inhibitor AZD8542 in an orthotopic model of pan-
creatic cancer produced by implantation of a mixture of PSCs
and cancer cells in the pancreas. AZD8542 was reported to reduce
tumor volume, metastasis, and Hedgehog downstream signaling
activity. Based on these encouraging pre-clinical reports, clinical
trials using Hedgehog inhibitors were commenced. Unfortunately
the phase II trial with IPI-926 had to be abandoned prematurely
due to decreased survival of patients in the treatment arm. The
lack of translation of the preclinical findings to the clinical setting
may reflect the fact that preclinical models do not fully capture
the heterogeneity of human pancreatic cancer, or that the pre-
clinical findings need to be better confirmed using a range of
experimental settings.
Taxanes such as Paclitaxel and Docetaxel have been used as
chemotherapeutic agents in a variety of cancers. The compounds
act by preventing microtubule depolymerization and interfering
with the cell cycle, but their use is hampered by their toxicity and
insolubility in water. Nanoparticle albumin complexed paclitaxel
(nab-paclitaxel) was developed to overcome the issues of solu-
bility and to enhance drug delivery through albumin facilitated
receptor-mediated transcytosis (Yardley, 2013). Administration
of nab-paclitaxel alone or in combination with gemcitabine in
a patient-tumor-derived subcutaneous xenograft model depleted
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the stroma in the tumors and increased perfusion via an increase
in blood vessel diameter with consequent improved delivery of
gemcitabine to tumor cells (Von Hoff et al., 2011). The mecha-
nisms mediating the effects of nab-paclitaxel on the stroma are
unknown. However, with regard to the anti-cancer effects, it is
postulated that the albumin in nab-paclitaxel is bound by secreted
protein acidic and rich in cysteine (SPARC), an albumin bind-
ing glycoprotein that is overexpressed in pancreatic cancer stroma
(Neuzillet et al., 2013), leading to accumulation of nab-paclitaxel
near tumor cells (Yardley, 2013). Furthermore, nab-paclitaxel
may increase the availability of gemcitabine within tumor tissue
by inducing the generation of reactive oxygen species within can-
cer cells, leading to inhibition of cytidine deaminase and conse-
quently decreasedmetabolic inactivation of gemcitabine (Yardley,
2013). As noted earlier, a recent Phase 3 trial has compared the
effects of nab-paclitaxel plus gemcitabine to gemcitabine alone in
patients with metastatic pancreatic cancer (Von Hoff et al., 2013).
The combination was found to significantly improve overall sur-
vival as well as progression-free survival compared to gemcitabine
alone (8.5 vs. 6.7 months and 5.5 vs. 3.7 months, respectively).
Although the improvements may be regarded as modest, the
results support the concept that targeting the stroma in addition
to cancer cells may be a potentially beneficial approach.
With regard to targeting the immune cells in PDAC stroma,
Beatty et al. (2011) have demonstrated in the KPC mouse
model of pancreatic cancer that activation of CD40, a mem-
ber of the TNF receptor superfamily, activates macrophages
in the stroma and results in apoptosis of cancer cells as well
as a reduction in stromal collagen. Activation of CD40 was
achieved by systemic administration of a CD40 agonist mon-
oclonal antibody to KPC mice. Using a similar approach in a
Phase I study in a small number of chemotherapy-naïve advanced
pancreatic cancer patients, the authors have reported that the
antibody in combination with gemcitabine was well-tolerated
with some evidence of anti-tumor activity, but with heteroge-
neous responses particularly with regard to metastatic lesions
(Beatty et al., 2013). Thus, larger randomized controlled tri-
als will be needed before the role of a CD40 agonist mono-
clonal antibody in pancreatic cancer treatment can be clearly
determined.
Other compounds that have been used to target the stroma,
but so far only in preclinical models, include:
i. Angiotensin II receptor antagonists: Angiotensin II, a com-
ponent of the renin-angiotensin system, has been shown
to induce PSC proliferation, ECM synthesis and migration,
and to increase the production of growth factors by PSCs.
Thus, angiotensin II receptor blockade, already in clinical
use in hypertension, has been recently assessed in a sub-
cutaneous xenograft model of pancreatic cancer. Using the
inhibitor olmasartan, Masamune et al. (2013) report a sig-
nificant decrease in primary tumor growth accompanied by
decreased α-SMA staining and ECM production in mice
injected with a mixture of PSCs and cancer cells, but not in
mice injected with cancer cells alone. Similarly, using losar-
tan (another Angiotensin II receptor inhibitor), Chauhan
et al. (2013) have reported decreased αSMA positive cells, and
reduced collagen and hyaluronan production in the stroma of
pancreatic cancer in an orthotopic mouse model.
ii. Pirfenidone (a pyridone compound known to be an effec-
tive antifibrotic agent in idiopathic pulmonary fibrosis):
Treatment with this compound using subcutaneous and
orthotopic models of pancreatic cancer has been reported
to decrease the growth of tumors produced by the injection
of a mixture of pancreatic cancer cells and PSCs, but not
that of tumors produced by cancer cells alone (Kozono et al.,
2013). In vitro studies showed that pirfenidone inhibited PSC
proliferation, invasion, and migration, and interrupted the
interaction between pancreatic cancer cells and PSCs; these
effects were associated with decreased expression of PDGF-
A, HGF, periostin, collagen type I, and fibronectin in PSCs, as
well as reduced PSC activation (decreased α-SMA expression)
(Kozono et al., 2013). The findings suggest that pirfenidone
regulates PSC function and inhibits cancer growth.
iii. PEGylated human recombinant PH20 hyaluronidase
(PEGPH20): This compound enzymatically degrades one
of the predominant components of the ECM, hyaluronan.
PEGPH20 treatment of KPC mice resulted in stromal
depletion and decompression of tumor vessels leading to
an increase in tumor vascular patency without increasing
vessel density. PEGPH20 also increased fenestrations in
endothelia and interendothelial junction gaps that increased
the permeability of the endothelium to macromolecules.
When combined with gemcitabine, PEGPH20 treatment
improved the delivery of gemcitabine to tumor cells inhibit-
ing tumor growth and extending the median survival of the
mice (Provenzano et al., 2012; Jacobetz et al., 2013).
iv. Phytonutrients ellagic acid and embelin: Ellagic acid is a
polyphenol found in a variety of nuts and fruit, while embelin
is a phytochemical from a Japanese herb Arsidae Japonicae.
These compounds have been reported to decrease prolifera-
tion and increase apoptosis of cancer cell as well as stellate
cells resulting in significantly reduced tumor volumes in a
xenograft model of pancreatic cancer (Edderkaoui et al.,
2013).
In conclusion, it is now abundantly clear that the prominent stro-
mal/desmoplastic reaction of pancreatic cancer can no longer be
dismissed as a mere epiphenomenon of carcinogenesis. Indeed,
available evidence strongly indicates that this stromal reaction,
and in particular the cells responsible for its production, PSCs,
likely play a key role at the earliest stages of pancreatic cancer
development. Therefore, all components of this reaction (stromal
cells and collagenousmatrix) warrant attention as potentially use-
ful, additional therapeutic targets in this disease. The challenge in
this field of research will be to ensure that preclinical testing is
carried out with experimental models (or a range of models) that
not only closely simulate the pathology, but also account for the
heterogeneity of human pancreatic cancer, so as to successfully
translate research findings into clinically effective therapies.
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